The disposition of zidovudine (ZDV) was examined during chronic oral dosing (300 mg every 4 h while awake) for 12 weeks in eight asymptomatic patients with hemophilia who were infected with the human immunodeficiency virus. Pharmacokinetic studies were conducted at the initiation of drug administration and after 6 and 12 weeks. Baseline liver function tests indicated normal values for bilirubin, albumin, and prothrombin time, while hepatic enzyme levels ranged from one to three times the normal levels. Initially, the mean peak ZDV concentration in plasma was 2,052 ng/ml with a range of 1,033 to 3,907 ng/ml, while during chronic dosing the peaks were 1,619 1,062 ng/ml and 1,711 ± 786 ng/ml at weeks 6 and 12, respectively. ZDV concentrations at 4 h declined to 77 53 ng/ml, 110 ± 43 ng/mI, and 101 ± 49 ng/ml at weeks 1, 6, and 12, respectively. Initially, the plasma concentration-versus-time decay in three patients was linear, with a mean half-life (tQ12) of 1.3 ± 0.5 h, while five patients had detectable concentrations in plasma after 4 h with an apparent delayed terminal-phase t112 of 4.8 ± 2.8 h. At week 6 the prolonged elimination pattern was noted in all patients (terminal t112 = 4.1 ± 2.0 h). No correlation between hepatic enzyme levels and t1/2 was noted. These findings suggest that ZDV may display a prolonged elimination phase during multiple dosing. Further studies utilizing a more sensitive assay may help to further define this later phase of ZDV elimination.
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Zidovudine (ZDV) is the only antiviral agent currently licensed for treatment of symptomatic human immunodeficiency virus (HIV) infection (4) . A pharmacologic consideration for the use of ZDV in hemophilia patients with HIV disease is the presence of chronic hepatitis among many of these patients and the potential for impaired drug metabolism (2, 3, 6, (8) (9) (10) . A recent report on the disposition of a single oral dose of ZDV in patients with hemophilia described considerable variability with regard to the concentrations in plasma attained (12) . The present study was conducted to extend these initial findings and to examine the pharmacokinetics of oral ZDV in asymptomatically HIV-infected hemophilia patients during chronic oral administration.
MATERIALS AND METHODS
Eight stable hemophilia patients without cardiac, gastrointestinal, renal, or other hematologic disease were admitted to the study after informed consent was obtained. All patients had antibodies to HIV as determined by enzymelinked immunosorbent assays and Western blot (immunoblot) tests. Serum chemistries, complete blood counts, peripheral T-helper cell counts, and serum p24 antigen levels were determined throughout the study period. Patients were excluded if they were receiving any drugs which theoretically could have altered hepatic glucuronidation of ZDV. After a patient was admitted to the Clinical Research Center at the University of Rochester, an intravenous catheter was placed and patency was maintained with a dilute heparin solution for each pharmacokinetic study, the patient was maintained without food for 6 h before and 2 h after oral drug administration, and all subsequent doses of ZDV were discontinued until discharge. After the completion of a 24-h intravenous study, a single oral ZDV dose (300 mg) was * Corresponding author.
administered and blood samples were obtained at 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 h. Serum was obtained by centrifugation and stored at -70°C until assayed. The patients were then discharged and instructed to take 300 mg of ZDV (three 100-mg capsules) every 4 h while awake for a 12-week period. Pharmacokinetic studies were repeated after 6 and 12 weeks as described above.
ZDV was measured in plasma with a high-pressure liquid chromatography (HPLC) technique originally described by Good et al. (5) . Plasma standards (5,000 to 38 ng/ml) and unknown ZDV concentrations were determined by calculation of the ratio of the corresponding peak area to the area of the internal standard. Linear regression was used to determine the unknown sample concentrations. High (4,000 ng/ ml) and low (200 ng/ml) quality control samples for ZDV were analyzed with each set of patient samples. The intraday relative standard deviations were 7.3 and 8% for the high and low quality controls, respectively. The lower limit of ZDV detection was 38 ng/ml, and data presented in the Results section reflect only those time points at which the ZDV concentration was higher than the lower limit of detection. The interday relative standard deviation for the standard of 38 ng/ml was 10.2%. In addition, we participated in two quality control programs sponsored by Burroughs Wellcome Laboratories and the AIDS Clinical Trials Group.
The plasma concentration data were analyzed, using both a noncompartmental pharmacokinetic technique (14) and a multicompartmental, nonlinear regression analysis (NON-LIN [11] ). The following parameters were determined: area under the plasma concentration-versus-time curve (AUC); elimination rate constant, calculated as the slope of the terminal phase of the log-linear plasma concentration-ver- Pharmacokinetics. ZDV was rapidly absorbed, with the peak concentration occurring at 0.5 to 1.0 h. The mean peak ZDV concentrations were 2,052 ± 970 ng/ml (week 1), 1,619 + 1,062 ng/ml (week 6), and 1,711 ± 786 ng/ml (week 12) (P > 0.05). Concentrations in plasma declined in a linear fashion with mean 4-h concentrations of 77 ± 53 ng/ml (week 1), 110 + 43 ng/ml (week 6), and 101 ± 49 ng/ml (week 12) (P > 0.05). Individual concentrations in plasma are presented in Table 2 .
The mean AUCs were 3,216 ± 1,722, 2,756 ± 712, and 2,588 ± 842 ng. h/mi at weeks 1, 6, and 12, respectively. The segment of the total AUC for each study day that was extrapolated comprised 6.5, 13.6, and 9.8% of the total AUC, respectively. The mean CL.r0Ls were 1 (Fig. 1, top) . At week 6, all patients had detectable ZDV concentrations after 4 h, but the number of measurable time points varied among patients (Fig. 1,  middle) . Of the five patients studied at 12 weeks, two reverted to linear decays (mean terminal t1/2, 1.7 ± 0.2 h) and three retained delayed elimination patterns (mean terminal t112, 5.4 ± 2.7 h) (Fig. 1, bottom) . Table 3 summarizes the individual pharmacokinetic parameters.
DISCUSSION
The pharmacokinetic data obtained from this group of hemophilia patients indicate that a fixed-dose ZDV regimen resulted in a variable AUC both within and between patients during chronic therapy. Initially, the peak ZDV concentration in plasma ranged from 1,033 ng/ml (dose, 4.8 mg/kg) in patient 6 to 3,907 ng/ml (dose, 4.6 mg/kg) in patient 2. The fact that these two patients received the same dose (even when corrected for body weight) illustrates a potential drawback to the use of a standardized ZDV-dosing regimen because variable pharmacokinetics may lead to differing ZDV plasma levels. In addition to variations among patients, peak ZDV concentrations within a patient were unpredictable during chronic dosing. As shown in patient 2, peak ZDV concentrations decreased from an initial value of 3,907 ng/ml to 886 ng/ml at week 6. On the other hand, patient 5 had a twofold increase in peak concentration from week 1 to week 6. The observation that there was a poor correlation between the weight-normalized dose and peak concentrations suggested that intra-or interindividual patterns of ZDV adsorption or first-pass metabolism have been responsible for variations among patients. These data contrast with the minimal intersubject pharmacokinetic variability that has been previ- ously reported for patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) (1, 7) .
In addition to variable bioavailability, the distribution and elimination pattern of ZDV in our hemophilia patients was different from previous data obtained from AIDS or ARC patients. Klecker et al. (7) and Blum et al. (1) reported the disposition of ZDV in AIDS and ARC patients who received oral doses of 2 to 5 mg/kg every 4 h. In both reports, ZDV disposition followed a monoexponential decline during oral dosing and yielded a mean tl2 of 1 On the basis of the known intracellular site of action for ZDV, it seems reasonable that the disposition of this antiviral agent would be described by a multicompartmental pattern during chronic dosing. In summary, administration of ZDV to asymptomatically HIV-infected hemophilia patients over a 12-week period produced a wide range of ZDV concentrations in plasma. A prolohged pattern of ZDV elimination was observed during multiple dosing, and a longer terminal t112 than has been previously reported was noted. Clearly, the intracellular metabolism of ZDV to the active triphosphate moiety, as well as the cumulative nature of certain ZDV toxicities (13) , makes interpretation of extracellular pharmacokinetic observations difficult. However, the intra-and interpatient variations observed in this group of HIV-infected hemophilia patients suggest that during long-term ZDV administration, not all patients receiving a similar dosage will receive an equivalent systemic exposure to ZDV. More studies are needed to correlate extraceilular ZDV disposition with intracellular phosphorylation patterns and, ultimately, with an anti-HIV effect. In addition, the use of an assay with greater sensitivity (i.e., radioimmunoassay) may allow for a more accurate determination of ZDV elimination kinetics.
